Clinical Trials Directory

Trials / Unknown

UnknownNCT05441748

Walnut Consumption and Gut Microbiota

The Microbial and Metabolic Impact of Walnut Consumption in Adults With Obesity

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
30 (actual)
Sponsor
University of Illinois at Urbana-Champaign · Academic / Other
Sex
All
Age
25 Years – 75 Years
Healthy volunteers
Accepted

Summary

Obesity is a growing health issue that effects the majority of adults in the United States. Prevalence of other metabolic diseases are increased in obese adults, including systemic inflammation. There is emerging evidence that the gut microbiota have a mediating role in controlling inflammation by producing butyrate when ingested fiber is fermented. Since these microbes are modifiable by diet, the investigators plan to introduce walnuts to the diets of participants with obesity because they are rich in fiber and unsaturated fatty acids. The purpose of this study is to understand the impacts of walnut consumption on the gut microbiota and the effect they have on bile acid profiles and systemic inflammation. The investigators intention is to identify how these walnut-derived molecules influence Faecalibacterium spp., a butyrate producing microbe. Increased levels of butyrate have shown to decrease secondary bile acids and decrease inflammation.

Conditions

Interventions

TypeNameDescription
OTHERWalnutsThe intervention treatment will contain walnuts.
OTHERWalnut OilThe intervention treatment will contain walnut oil.
OTHERControlThe control treatment will contain corn oil.

Timeline

Start date
2022-06-01
Primary completion
2023-08-01
Completion
2024-07-01
First posted
2022-07-01
Last updated
2023-06-18

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT05441748. Inclusion in this directory is not an endorsement.